

## REMARKS

In response to the restriction requirement, Applicants have elected (with traverse) Group I. Thus, claims 1-5, 20-26, 35-37, 39, 40, 42, 43, and 54-56 are pending. By this amendment, claim 25 has been cancelled, and claims 3, 4, 20, 23, 24, 37, 39, 40, 42, 54 and 56 have been amended. The amendments are for clarity and/or accuracy, in response to the Examiner's suggestions. With respect to deletion to references to "monoclonal", the Examiner agreed that antibody 11D10 need not be monoclonal, which refers to an antibody's origin.

Applicants' representative appreciates the Examiner's careful attention and suggestions, and welcomes a telephone call to discuss any extant issues.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 304142000321. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: July 30, 1998

By: Catherine M. Polizzi  
Catherine M. Polizzi  
Registration No. 40,130

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5651  
Facsimile: (650) 494-0792